(2,3-difluorophenyl)-ethyl 4-methylbenzenesulfonate | 1239331-90-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2,3-difluorophenyl)-ethyl 4-methylbenzenesulfonate
• 英文别名: 2,3-difluorophenethyl 4-methylbenzenesulfonate；2-(2,3-Difluorophenyl)ethyl 4-methylbenzenesulfonate；2-(2,3-difluorophenyl)ethyl 4-methylbenzenesulfonate
• CAS: 1239331-90-8
• 化学式: C₁₅H₁₄F₂O₃S
• 分子量: 312.337
• InChiKey: XISIPONNYWHGFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2,3-difluorophenyl)-ethyl 4-methylbenzenesulfonate 在 溴 、 铁粉 、 magnesium 、 1,2-二溴乙烷 、 lithium bromide 作用下， 以 乙醚 、 氯仿 、 丙酮 为溶剂， 反应 4.5h， 生成 1-Bromo-2-ethyl-3,4-difluorobenzene
  参考文献：
  名称：

  Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)

  摘要：

  A series of novel, highly potent, selective, and ATP-competitive mammalian target of rapamycin (mTOR) inhibitors based on a benzoxazepine scaffold have been identified. Lead optimization resulted in the discovery of inhibitors with low nanomolar activity and greater than 1000-fold selectivity over the closely related PI3K kinases. Compound 28 (XL388) inhibited cellular phosphorylation of mTOR complex 1 (p-p70S6K, pS6, and p-4E-BP1) and mTOR complex 2 (pAKT (S473)) substrates. Furthermore, this compound displayed good pharmacokinetics and oral exposure in multiple species with moderate bioavailability. Oral administration of compound 28 to athymic nude mice implanted with human tumor xenografts afforded significant and dose-dependent antitumor activity.

  DOI：

  10.1021/jm3007933
• 作为产物：
  描述：

  2,3-二氟苯乙酸 在 dimethyl sulfide borane 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 10.0h， 生成 (2,3-difluorophenyl)-ethyl 4-methylbenzenesulfonate
  参考文献：
  名称：

  Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)

  摘要：

  A series of novel, highly potent, selective, and ATP-competitive mammalian target of rapamycin (mTOR) inhibitors based on a benzoxazepine scaffold have been identified. Lead optimization resulted in the discovery of inhibitors with low nanomolar activity and greater than 1000-fold selectivity over the closely related PI3K kinases. Compound 28 (XL388) inhibited cellular phosphorylation of mTOR complex 1 (p-p70S6K, pS6, and p-4E-BP1) and mTOR complex 2 (pAKT (S473)) substrates. Furthermore, this compound displayed good pharmacokinetics and oral exposure in multiple species with moderate bioavailability. Oral administration of compound 28 to athymic nude mice implanted with human tumor xenografts afforded significant and dose-dependent antitumor activity.

  DOI：

  10.1021/jm3007933

文献信息

• [EN] BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER<br/>[FR] DÉRIVÉS BENZOXAZEPIN-4-(5H)-YLE ET LEUR UTILISATION POUR TRAITER LE CANCER
  申请人：EXELIXIS INC

  公开号：WO2010118208A1

  公开（公告）日：2010-10-14

  The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

  这项发明涉及公式I的化合物及其药用可接受的盐或溶剂合物，以及制备和使用这些化合物的方法。
• Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain
  作者：Hak Kyun Yang、Woo Seung Son、Keon Seung Lim、Gun Hee Kim、Eun Jeong Lim、Changdev G. Gadhe、Jae Yeol Lee、Kyu-Sung Jeong、Sang Min Lim、Ae Nim Pae

  DOI：10.1080/14756366.2018.1513926

  日期：2018.1.1

  T-type channel inhibitors showed promising in vivo efficacy in neuropathic pain animal models and are being investigated in clinical trials. Herein we report development of novel pyrrolidine-based T-type calcium channel inhibitors by pharmacophore mapping and structural hybridisation followed by evaluation of their Cav3.1 and Cav3.2 channel inhibitory activities. Among potent inhibitors against both

  神经性疼痛的治疗是迫切的医疗需求之一，T型钙通道是神经性疼痛的有希望的治疗靶点。几种有效的T型通道抑制剂在神经性疼痛动物模型中显示出有希望的体内功效，并且正在临床试验中进行研究。在本文中，我们报告了通过药效基团定位和结构杂交，然后对其Cav3.1和Cav3.2通道抑制活性进行评估的新型基于吡咯烷的T型钙通道抑制剂的开发。根据体内药代动力学研究，在针对Cav3.1和Cav3.2通道的有效抑制剂中，一种基于体外ADME特性的有前途的化合物20n在大鼠中显示出令人满意的血浆和脑暴露。
• Inhibitors of mTOR and Methods of Making and Using
  申请人：Anand Neel Kumar

  公开号：US20100305093A1

  公开（公告）日：2010-12-02

  The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

  本发明涉及公式I的化合物及其药学上可接受的盐或溶剂化物，以及制备和使用这些化合物的方法。